

2021 BOARD OF TRUSTEES

BOARD OFFICERS

Bruce Flanz • Queens
Chair

Michael Spicer • Yonkers
Chair-Elect

Jose Acevedo, MD • Geneva
Secretary

Thomas Carman • Watertown
Treasurer

Thomas Quatroche Jr., PhD • Buffalo
Immediate Past Chair

Richard Murphy • Oceanside
Past Chair

Steven Corwin, MD • New York
Past Chair

BOARD MEMBERS

Former Chairs

Michael Dowling • New Hyde Park

Steven Goldstein • Rochester

Herbert Pardes, MD • New York

Class of 2021

Victor Ayala • Brooklyn

Scott Berlucchi • Auburn

John Carrigg • Binghamton

Michael Finegan • Albany

Evan Flatow, MD • New York

Laura Forese, MD • New York

Kenneth Gibbs • Brooklyn

Carol Gomes • Stony Brook

Kenneth Kaushansky, MD • Stony Brook

John Remillard • Elizabethtown

Class of 2022

LaRay Brown • Brooklyn

Jeannie Cross • Saranac Lake

Joan Cusack-McGuirk • Newburgh

Alan Guerci, MD • Rockville Centre

Steven Kelley • Ellenville

Mary LaRowe • Dunkirk

Daniel Messina, PhD • Staten Island

David Perlstein, MD • Bronx

Kenneth Roberts • Port Jefferson

Dierdra Sorrell • Star Lake

Robert Spolzino, JD • New Hyde Park

Hugh Thomas, Esq. • Rochester

Class of 2023

Alexander Balko • Brooklyn

Kimberly Boynton • Syracuse

Susan Fox • White Plains

Sylvia Getman • Saranac Lake

Susan Holliday • Rochester

Allegra Jaros • Buffalo

Mary Leahy, MD • Suffern

Wayne Riley, MD • Brooklyn

Caryn Schwab • Queens

Dianne Shugrue • Glens Falls

Mark Solazzo • New Hyde Park

Mike Stapleton • Canandaigua

Mark Sullivan • Buffalo

Vincent Verdile, MD • Albany

Allied Association Chairs

Robert Chaloner • Southampton

Michelle LeBeau • Plattsburgh

Dustin Riccio, MD • Newark

Charles Urlaub • Lewiston

January 4, 2021

Timothy J. Shea
Acting Administrator
Drug Enforcement Agency
Department of Justice, Attn:
DEA Federal Register Representative/DPW, Diversion Control Division
8701 Morrissette Drive, Springfield, VA 22152

Submitted electronically via [regulations.gov](https://www.regulations.gov)

RE: RIN: 1117-AB55 Implementation of the “Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018” Dispensing and Administering Controlled Substances for Medication-Assisted Treatment (DEA-499)

Dear Acting Administrator Shea:

The Healthcare Association of New York State, on behalf of our member nonprofit and public hospitals, nursing homes, home health agencies and other healthcare providers, welcomes the opportunity to respond to the Drug Enforcement Administration’s interim final rule on the implementation of provisions in the SUPPORT Act, containing changes to 21 Code of Federal Regulations, Parts 1301 and 1306.

Healthcare providers continue to face barriers to prescribing evidence-based treatment like buprenorphine and other medication-assisted treatment. Previous caps on patient volume for MAT administration hindered the expansion and accessibility.

This rule would update regulations to reflect the increased cap on the number of patients that a physician or other clinician can treat, including up to 275 patients if they meet certain requirements. Previous caps at 30 and 100 arbitrarily limited the expansion of opioid use disorder treatment. HANYYS supports raising the cap on the number of patients a qualified provider can treat.

HANYYS supports efforts by the DEA to align regulations with the SUPPORT Act, and implement its requirements. The following flexibilities offered in the interim regulations have been especially important for expanding access to care:

- treatment of up to 100 patients in the first year providers head Drug Assisted Treatment Act-waivered instead of 30;
- ability for nurse practitioners and physician assistants to become DATA-waivered;

- inclusion of clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives among qualifying providers;
- eligibility for waiver status among medical school graduates with at least eight hours of training on treating and managing opioid-dependent patients; and
- allowance for medication to be dispensed to providers' registered locations, rather than only the ultimate user or research subject.

However, despite the allowance for more types of providers to become DATA-waivered, the 24-hour training requirement to become DATA-waiver eligible is a persistent barrier. HANYS urges DEA and other stakeholders to reassess the 24-hour training requirement.

Under the SUPPORT Act, providers have to administer injectable buprenorphine within 14 days of the date the medication is received. The SUPPORT Act grants DEA the authority to modify the 14-day administration limit; however, the interim final rule retains the 14-day limit.

This 14-day timeframe does not account for delays in shipping, insurance authorization and other external factors. Furthermore, if a long-acting injectable buprenorphine product is not administered within 14 days of receipt, it must be destroyed.

HANYS urges the DEA to increase the number of days a practitioner can administer buprenorphine after receipt of the medication from 14 days to 60 days pursuant to authority granted under the SUPPORT Act.

Thank you for the opportunity to provide feedback on this interim final rule. If you have questions regarding our comments, please contact Sarah DuVall, director, behavioral health, at (518) 431-7769 or sduvall@hanys.org.

Sincerely,



Jeffrey Gold
Senior Vice President and Special Counsel, Managed Care and Insurance